Reports / Neurology Reports
The multiple sclerosis (MS) market is more dynamic than ever with more than 14 disease-modifying therapies (DMTs) currently available. In addition, evolving attitudes around safety issues balanced with earlier treatment with aggressive therapy has made the competitive environment increasingly complex. With the launch of the first anti-CGRP agent, the migraine market gains a new class which will shift current competitive patterns.
Rapid turnaround monitor for highly dynamic healthcare segments
- Multiple Sclerosis Canada (coming 2019)
- Symptomatic Agents in Multiple Sclerosis (coming 2019)
Retrospective analysis of 1,000 +/- patient charts
Learn more about our work in the neurology space.